Therapeutic treatment of marburg and ravn virus infection in nonhuman primates with a human monoclonal antibody

Science Translational Medicine

Volumn 9, Issue 384, 2017, Pages

  Mire, Chad E ^a   Geisbert, Joan B ^a   Borisevich, Viktoriya ^a   Fenton, Karla A ^a   Agans, Krystle N ^a   Flyak, Andrew I ^b   Deer, Daniel J ^a   Steinkellner, Herta ^c   Bohorov, Ognian ^d   Bohorova, Natasha ^d   Goodman, Charles ^d   Hiatt, Andrew ^d   Kim, Do H ^d   Pauly, Michael H ^d   Velasco, Jesus ^d   Whaley, Kevin J ^d   Crowe, James E ^b   Zeitlin, Larry ^d   Geisbert, Thomas W ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^d Mapp Biopharmaceutical Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HUMAN MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MR191 N; MONOCLONAL ANTIBODY MR78 N; MONOCLONAL ANTIBODY MR82 N; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CROSS PROTECTION; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG SCREENING; FEMALE; FILOVIRIDAE; FILOVIRUS INFECTION; GUINEA PIG MODEL; INFECTION PREVENTION; INOCULATION; MARBURG HEMORRHAGIC FEVER; MARBURGVIRUS; NONHUMAN; RAVN VIRUS; RAVN VIRUS INFECTION; RHESUS MONKEY; SINGLE DRUG DOSE; SURVIVAL ANALYSIS; SURVIVAL RATE; TRANSIENT EXPRESSION; VIRUS VIRULENCE; ANIMAL; GUINEA PIG; HUMAN; MACACA FASCICULARIS; PHYSIOLOGY; PILOT STUDY; VIROLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; CROSS PROTECTION; FILOVIRIDAE; FILOVIRIDAE INFECTIONS; GUINEA PIGS; HUMANS; MACACA FASCICULARIS; MACACA MULATTA; MARBURG VIRUS DISEASE; MARBURGVIRUS; PILOT PROJECTS;

EID: 85017420711     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aai8711     Document Type: Article

References (36)

1. A. Sanchez, H. Feldmann, T. W. Geisbert, Filoviridae: Marburg and Ebola viruses, in Fields Virology, D. M. Knipe, P. M. Howley, Eds. (Lippincott Williams & Wilkins, 2013), pp. 923-956.
2. M. Leitenberg, R. A. Zilinskas, The Soviet Biological Weapons Program: A History (Harvard Univ. Press, 2012).
3. D. M. Ecker, S. D. Jones, H. L. Levine, The therapeutic monoclonal antibody market. MABS 7, 9-14 (2015).
4. A. Casadevall, M. D. Scharff, Return to the past: The case for antibody-based therapies in infectious diseases. Clin. Infect. Dis. 21, 150-161 (1995).
5. L. Zeitlin, R. A. Cone, T. R. Moench, K. J. Whaley, Preventing infectious disease with passive immunization. Microbes Infect. 2, 701-708 (2000).
6. T. W. Geisbert, C. E. Mire, J. B. Geisbert, Y.-P. Chan, K. N. Agans, F. Feldmann, K. A. Fenton, Z. Zhu, D. S. Dimitrov, D. P. Scott, K. N. Bossart, H. Feldmann, C. C. Broder, Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody. Sci. Transl. Med. 6, 242ra282 (2014).
7. K. N. Bossart, T. W. Geisbert, H. Feldmann, Z. Zhu, F. Feldmann, J. B. Geisbert, L. Yan, Y.-R. Feng, D. Brining, D. Scott, Y. Wang, A. S. Dimitrov, J. Callison, Y.-P. Chan, A. C. Hickey, D. S. Dimitrov, C. C. Broder, B. Rockx, A neutralizing human monoclonal antibody protects African green monkeys from Hendra virus challenge. Sci. Transl. Med. 3, 105ra103 (2011).
8. J. Pettitt, L. Zeitlin, D. H. Kim, C. Working, J. C. Johnson, O. Bohorov, B. Bratcher, E. Hiatt, S. D. Hume, A. K. Johnson, J. Morton, M. H. Pauly, K. J. Whaley, M. F. Ingram, A. Zovanyi, M. Heinrich, A. Piper, J. Zelko, G. G. Olinger, Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci. Transl. Med. 5, 199ra113 (2013).
9. X. Qiu, G. Wong, J. Audet, A. Bello, L. Fernando, J. B. Alimonti, H. Fausther-Bovendo, H. Wei, J. Aviles, E. Hiatt, A. Johnson, J. Morton, K. Swope, O. Bohorov, N. Bohorova, C. Goodman, D. Kim, M. H. Pauly, J. Velasco, J. Pettitt, G. G. Olinger, K. Whaley, B. Xu, J. E. Strong, L. Zeitlin, G. P. Kobinger, Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514, 47-53 (2014).
10. W. R. Strohl, Antibody discovery: Sourcing of monoclonal antibody variable domains. Curr. Drug Discov. Technol. 11, 3-19 (2014).
11. J. E. Crowe Jr., Recent advances in the study of human antibody responses to influenza virus using optimized human hybridoma approaches. Vaccine 27 (suppl.6), G47-G51 (2009).
12. S. A. Smith, R. de Alwis, N. Kose, A. P. Durbin, S. S. Whitehead, A. M. de Silva, J. E. Crowe Jr., Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. J. Infect. Dis. 207, 1898-1908 (2013).
13. S. A. Smith, L. A. Silva, J. M. Fox, A. I. Flyak, N. Kose, G. Sapparapu, S. Khomadiak, A. W. Ashbrook, K. M. Kahle, R. H. Fong, S. Swayne, B. J. Doranz, C. E. McGee, M. T. Heise, P. Pal, J. D. Brien, S. K. Austin, M. S. Diamond, T. S. Dermody, J. E. Crowe Jr., Isolation and characterization of broad and ultrapotent human monoclonal antibodies with therapeutic activity against chikungunya virus. Cell Host Microbe 18, 86-95 (2015).
14. Z. A. Bornholdt, H. L. Turner, C. D. Murin, W. Li, D. Sok, C. A. Souders, A. E. Piper, A. Goff, J. D. Shamblin, S. E. Wollen, T. R. Sprague, M. L. Fusco, K. B. J. Pommert, L. A. Cavacini, H. L. Smith, M. Klempner, K. A. Reimann, E. Krauland, T. U. Gerngross, K. D. Wittrup, E. O. Saphire, D. R. Burton, P. J. Glass, A. B. Ward, L. M. Walker, Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science 351, 1078-1083 (2016).
15. A. I. Flyak, P. A. Ilinykh, C. D. Murin, T. Garron, X. Shen, M. L. Fusco, T. Hashiguchi, Z. A. Bornholdt, J. C. Slaughter, G. Sapparapu, C. Klages, T. G. Ksiazek, A. B. Ward, E. O. Saphire, A. Bukreyev, J. E. Crowe Jr., Mechanism of human antibody-mediated neutralization of Marburg virus. Cell 160, 893-903 (2015).
16. A. Giritch, S. Marillonnet, C. Engler, G. van Eldik, J. Botterman, V. Klimyuk, Y. Gleba, Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors. Proc. Natl. Acad. Sci. U.S.A. 103, 14701-14706 (2006).
17. R. W. Cross, K. A. Fenton, J. B. Geisbert, H. Ebihara, C. E. Mire, T. W. Geisbert, Comparison of the pathogenesis of the Angola and Ravn strains of Marburg virus in the outbred guinea pig model. J. Infect. Dis. 212 (suppl.2), S258-S270 (2015).
18. R. Ursic-Bedoya, C. E. Mire, M. Robbins, J. B. Geisbert, A. Judge, I. MacLachlan, T. W. Geisbert, Protection against lethal Marburg virus infection mediated by lipid encapsulated small interfering RNA. J. Infect. Dis. 209, 562-570 (2014).
19. C. E. Mire, J. B. Geisbert, K. M. Versteeg, N. Mamaeva, K. N. Agans, T. W. Geisbert, J. H. Connor, A single-vector, single-injection trivalent filovirus vaccine: Proof of concept study in outbred guinea pigs. J. Infect. Dis. 212 (suppl.2), S384-S388 (2015).
20. E. P. Thi, C. E. Mire, R. Ursic-Bedoya, J. B. Geisbert, A. C. H. Lee, K. N. Agans, M. Robbins, D. J. Deer, K. A. Fenton, I. MacLachlan, T. W. Geisbert, Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA. Sci. Transl. Med. 6, 250ra116 (2014).
21. T. W. Geisbert, K. M. Daddario-DiCaprio, J. B. Geisbert, H. A. Young, P. Formenty, E. A. Fritz, T. Larsen, L. E. Hensley, Marburg virus Angola infection of rhesus macaques: Pathogenesis and treatment with recombinant nematode anticoagulant protein c2. J. Infect. Dis. 196 (suppl.2), S372-S381 (2007).
22. G. G. Olinger Jr., J. Pettitt, D. Kim, C. Working, O. Bohorov, B. Bratcher, E. Hiatt, S. D. Hume, A. K. Johnson, J. Morton, M. Pauly, K. J. Whaley, C. M. Lear, J. E. Biggins, C. Scully, L. Hensley, L. Zeitlin, Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc. Natl. Acad. Sci. U.S.A. 109, 18030-18035 (2012).
23. E. D. Johnson, B. K. Johnson, D. Silverstein, P. Tukei, T. W. Geisbert, A. N. Sanchez, P. B. Jahrling, Characterization of a new Marburg virus isolated from a 1987 fatal case in Kenya. Arch. Virol. Suppl.11, 101-114 (1996).
24. P. B. Jahrling, J. Geisbert, J. R. Swearengen, G. P. Jaax, T. Lewis, J. W. Huggins, J. J. Schmidt, J. W. LeDuc, C. J. Peters, Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch. Virol. Suppl.11, 135-140 (1996).
25. P. B. Jahrling, J. B. Geisbert, J. R. Swearengen, T. Larsen, T. W. Geisbert, Ebola hemorrhagic fever: Evaluation of passive immunotherapy in nonhuman primates. J. Infect. Dis. 196 (suppl.2), S400-S403 (2007).
26. W. B. Oswald, T. W. Geisbert, K. J. Davis, J. B. Geisbert, N. J. Sullivan, P. B. Jahrling, P. W. H. I. Parren, D. R. Burton, Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLOS Pathog. 3, e9 (2007).
27. J. M. Dye, A. S. Herbert, A. I. Kuehne, J. F. Barth, M. A. Muhammad, S. E. Zak, R. A. Ortiz, L. I. Prugar, W. D. Pratt, Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc. Natl. Acad. Sci. U.S.A. 109, 5034-5039 (2012).
28. A. L. Schmaljohn, Protective antiviral antibodies that lack neutralizing activity: Precedents and evolution of concepts. Curr. HIV Res. 11, 345-353 (2013).
29. D. Corti, J. Misasi, S. Mulangu, D. A. Stanley, M. Kanekiyo, S. Wollen, A. Ploquin, N. A. Doria-Rose, R. P. Staupe, M. Bailey, W. Shi, M. Choe, H. Marcus, E. A. Thompson, A. Cagigi, C. Silacci, B. Fernandez-Rodriguez, L. Perez, F. Sallusto, F. Vanzetta, G. Agatic, E. Cameroni, N. Kisalu, I. Gordon, J. E. Ledgerwood, J. R. Mascola, B. S. Graham, J.-J. Muyembe-Tamfun, J. C. Trefry, A. Lanzavecchia, N. J. Sullivan, Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 351, 1339-1342 (2016).
30. American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee, Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 134, e820-e638 (2014).
31. T. W. Geisbert, J. E. Strong, H. Feldmann, Considerations in the use of nonhuman primate models of Ebola virus and Marburg virus infection. J. Infect. Dis. 212 (suppl.2), S91-S97 (2015).
32. L. Zeitlin, O. Bohorov, N. Bohorova, A. Hiatt, D. H. Kim, M. H. Pauly, J. Velasco, K. J. Whaley, D. L. Barnard, J. T. Bates, J. E. Crowe Jr., P. A. Piedra, B. E. Gilbert, Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model. MAbs 5, 263-269 (2013).
33. A. Hiatt, N. Bohorova, O. Bohorov, C. Goodman, D. Kim, M. H. Pauly, J. Velasco, K. J. Whaley, P. A. Piedra, B. E. Gilbert, L. Zeitlin, Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc. Natl. Acad. Sci. U.S.A. 111, 5992-5997 (2014).
34. L. Zeitlin, J. B. Geisbert, D. J. Deer, K. A. Fenton, O. Bohorov, N. Bohorova, C. Goodman, D. Kim, A. Hiatt, M. H. Pauly, J. Velasco, K. J. Whaley, F. Altmann, C. Gruber, H. Steinkellner, A. N. Honko, A. I. Kuehne, M. J. Aman, S. Sahandi, S. Enterlein, X. Zhan, D. Enria, T. W. Geisbert, Monoclonal antibody therapy for Junin virus infection. Proc. Natl. Acad. Sci. U.S.A. 113, 4458-4463 (2016).
35. L. Zeitlin, J. Pettitt, C. Scully, N. Bohorova, D. Kim, M. Pauly, A. Hiatt, L. Ngo, H. Steinkellner, K. J. Whaley, G. G. Olinger, Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc. Natl. Acad. Sci. U.S.A. 108, 20690-20694 (2011).
36. K. M. Daddario-DiCaprio, T. W. Geisbert, U. Ströher, J. B. Geisbert, A. Grolla, E. A. Fritz, L. Fernando, E. Kagan, P. B. Jahrling, L. E. Hensley, S. M. Jones, H. Feldmann, Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: An efficacy assessment. Lancet 367, 1399-1404 (2006).